Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Bladder Cancer Pipeline Insight 2025' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bladder Cancer Research. Learn more about our innovative pipeline today! @ Bladder Cancer Pipeline Outlook
Key Takeaways from the Bladder Cancer Pipeline Report
In March 2025, Janssen Research & Development LLC announced a phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.
In March 2025, Fidia Farmaceutici announced a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy.
In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive and cancer free longer than those who receive placebo and pembrolizumab, and to learn about the safety of V940, pembrolizumab, and EV, and if people tolerate them.
DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
The leading Bladder Cancer Companies such as UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
Promising Bladder Cancer Therapies such as Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
Stay informed about the cutting-edge advancements in Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Bladder Cancer Clinical Trials Assessment
Bladder cancer Emerging Drugs Profile
UGN-102: UroGen Pharma Ltd.
UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen's proprietary RTGel® technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.
APL 1202 : Asieris Pharmaceuticals
APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.
Trilaciclib: G1 Therapeutics, Inc.
Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.
Catumaxomab: LintonPharm Co.,Ltd.
Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.
VAX 014: Vaxiion Therapeutics
VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either α3β1 or α5β1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.
Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ Bladder Cancer Unmet Needs
Bladder Cancer Companies
UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Bladder Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Discover the latest advancements in Bladder Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bladder Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Bladder Cancer Pipeline Report
Coverage- Global
Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ Bladder Cancer Drugs and Companies
Table of Content
Introduction
Bladder Cancer Executive Summary
Bladder Cancer: Overview
Bladder Cancer Pipeline Therapeutics
Bladder Cancer Pipeline Therapeutic Assessment
Late Stage Products (Phase III)
UGN-102: UroGen Pharma Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Trilaciclib: G1 Therapeutics, Inc.
Early Stage Products (Phase I)
VAX 014: Vaxiion Therapeutics
Inactive Products
Bladder Cancer Key Companies
Bladder Cancer Key Products
Bladder Cancer - Unmet Needs
Bladder Cancer - Market Drivers and Barriers
Bladder Cancer - Future Perspectives and Conclusion
Bladder Cancer Analyst Views
Bladder Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Breaking Down Thursday's Top 3 Unusually Active Options
Happy Friday to Barchart readers, everywhere. I don't know what the weather is like where you live, but here in Halifax, on Canada's east coast, we are headed into what is expected to be the 13th consecutive bad-weather weekend. It's rained every weekend since March. The rain we are receiving is much-needed in Manitoba and Saskatchewan, where wildfires have forced over 33,000 people to evacuate their homes. I sure hope some of our rain heads west sooner rather than later. They need it in a big way. On tap this morning was the Department of Labor's jobs report for May. It was decent with 139,000 jobs added last month, down from 147,000 in April, but 9,000 higher than the economists' forecast. The unemployment rate remained at 4.2%. As a result of the resilient jobs report, the S&P Futures are moving higher with about half an hour to the open. Let's see if we can finish the week on a high note. In Thursday's trading, there were 1,399 unusually active options, split almost evenly between puts (705) and calls (694). Of the top 100 by Vol/OI (volume-to-open-interest) ratios, these three had the highest. Have an excellent weekend. Visa (V) Visa's (V) Jan. 15/2027 $400 call was numero uno with a Vol/OI ratio of 81.86. The profit probability is so-so at 27.64%. The expected move is 20.17% in either direction. With nearly 20 months until expiration, there's a lot of water to go under the bridge. While analysts love the stock --of the 38 covering V stock, 33 rate it a Buy (4.63 out of 5), with a 383.81 mean target price--there is a lot that can go wrong in the global economy in the next 12-18 months resulting from tariffs and uncertain trading relationships, forcing the U.S. and other developed markets into a recession. Visa generates revenue by charging interchange fees to financial institutions that utilize its global network for processing, clearing, and settling transactions. If the economy goes into a downturn, consumers and businesses spend less, resulting in fewer financial transactions that require processing. However, Mizuho Securities analyst Dan Dolev recently upgraded V stock to Outperform (Buy) from Neutral (Hold), while raising his target price by $57 to $425, within shouting distance of the call's $437.45 breakeven. 'We see more reason for optimism as the remaining cash-to-card runway in the US is longer than previously expected,' Barron's reported Dolev's comments on June 5. 'This leaves room for another decade of solid top-line growth domestically.' As the analyst suggested, Visa and Mastercard (MA) have 'arguably the highest quality duopoly in the world,' so over the long haul, their share price should continue to move higher. Over the past 20 months (Oct. 6, 2023, through June 5, 2025), Visa's shares have appreciated by 56%. To break even on the Jan. 15/2025 $400 call, it needs only to appreciate by 18.64%. That is very doable. With a net debit of $3,705, just 9.2% of the $400 strike, the risk/reward proposition is more than reasonable. If Novo Nordisk (NVO) The Danish maker of Ozempic and Wegovy had the second-highest Vol/OI ratio yesterday of 71.77. The volume of 12,129 accounted for nearly 23% of the overall total. The 53,351 was the stock's highest daily volume since May 19. Of the 12,129 contracts traded for the June 13 $66 put, one order accounted for 85% of the volume. Some big hitter had a hunch. Novo Nordisk's (NVO) stock appears to have bottomed in mid-April at $57. It's up 27% in the seven weeks since. Barchart's Technical Opinion rates it a 40% Sell with the 20-day moving average signaling Buy. In mid-May, the company's board ousted CEO Lars Fruergaard Jorgensen after eight years running the drugmaker. Jorgensen had spent his entire career with Novo Nordisk. There is no question that, at least in the past 6-12 months, the bloom has come off the rose for NVO stock. With poor results for CagriSema, its next-generation weight-loss drug set for release in 2026, increased competition in the weight loss space from Eli Lilly (LLY), and lower growth forecasts, it will be some time before investors pile back on to the Novo Nordisk train. However, with just a 7.54% profit probability from the long put bet, the big hitter was likely counting on a virtually guaranteed, 10.5% annualized return by selling the puts instead. Worst case scenario: They're able to buy NVS stock at a slightly lower entry point should it fall below $66, and the buyer exercises their right to sell. I like that trade a lot. Roblox (RBLX) This last one should be filed under 'a wing and a prayer' or 'Hail Mary,' with a profit probability of just 3.13%. Roblox (RBLX) stock would have to drop by nearly 20% in the next week to have any chance of profiting from the $76 put strike. I can't remember the last time I wrote about Roblox, whose online platform allows users to create, share, and play virtual experiences and games. RBLX stock is alive and well, trading up 66% in 2025 and 169% over the past 12 months. Over the past five years, on three occasions (June 2022, December 2022, and September 2023), its shares traded at around $27. They're now not too far off from the November 2021 all-time high of $141.60. Roblox has hit 63 new 52-week highs in the past 12 months. Of the 24 analysts covering its stock, 16 rate it a Buy (4.13 out of 5), with a mean target price of $76.88, well below its current share price. I'm often confused by analysts assigning a Buy rating to a stock but with a target price below its current share price. I realize this means that the bullish analysts feel its share price has gotten ahead of itself. So, why not rate it Hold? That's a discussion for another day. As the company stated in May, it anticipates generating as much as $930 million in free cash flow in 2025, based on $4.37 billion in revenue, resulting in a 21.3% margin, the highest levels for both in its history. Yes, it still is losing a bundle--Roblox guidance calls for a net loss in 2025 between $977 million and $1.04 billion--but positive free cash flow is the name of the game and it could go over $1 billion as early as this year with a bit of luck, but definitely in 2026. Even if it loses $1 billion annually for the next three years, Roblox has sufficient liquidity to maintain operations—net cash of $3.5 billion as of March 31—so it remains an attractive stock for speculative investors. If you sold the $76 put for $0.02 in premium income, your annualized return on the bet would be 1.4% [0.02 / $76 * 365 / 8]. Long or short, I'm not sure why someone made a trade for 7,000 $76 put contracts yesterday. There doesn't seem to be a profitable outcome either way. Of course, at $15 a contract, it's not a significant outlay. No harm, no foul, I guess.
Globe and Mail
2 days ago
- Globe and Mail
‘June dips are buying opportunities': CIBC's Mokhtari on his latest market views and 10 top stock picks
North American equity markets rallied sharply in May. The S&P/TSX Composite Index posted a 10-day rally last month, which pushed the index above 26,000 for the first time. This positive momentum is not over, according to CIBC's chief market technician Sid Mokhtari. He is forecasting a move above 27,000 in the months ahead. Mr. Mokhtari publishes a monthly report with his Top 10 stock ideas and his disciplined process continues to lead to portfolio outperformance. He screens and selects stocks from the largest 100 members by market capitalization within the S&P/TSX Composite Index. In the first five months of 2025, his portfolio of stock selections delivered a double-digit return of 11.4 per cent, compared to a 5.85 per cent gain for the broader index. His stock selections also outperformed the S&P/TSX Composite Index in 2024, 2023 and 2022 by 5.8 percentage points, 6.3 percentage points and 2.7 percentage points, respectively. For June, his Top 10 stock ideas include nine additions and one carryover from the prior month. They are: Aritzia (ATZ-T), Eldorado Gold (ELD-T), Exchange Income (EIF-T), Killam Apartment REIT (KMP-UN-T), MDA Space (MDA-T), NGEx Minerals (NGEX-T), Parkland (PKI-T), Shopify (SHOP-T), Sun Life (SLF-T), and the lone carryover is Power Corp. (POW-T). On June 3, I spoke with Mr. Mokhtari to get his technical take on the markets. We also delved into his June stock picks and ETFs with attractive technical setups. In a report that you published on June 1, you said both the TSX Composite Index and the S&P 500 exhibit a 'cup and handle' or 'pole and pennant' pattern. Could you break down these technical terms and what it suggests for future moves in these two indices? 'Pole and pennant' and 'cup and handle' patterns are typically associated with accumulation as well as uptrend continuation. With a 'pole and pennant', you see a surge in momentum and a sharp rise in a share price or an index. Then, you have a shallow consolidation in a short time frame, and that needs to resolve itself in the direction of the momentum burst. We estimate that we saw capitulation in April. Coming off the April lows, breadth began to exhibit an expansionary phase and momentum surged. This forced broader indices to shift upward in a very sharp fashion, creating almost a V-shaped recovery that created the pole. If we're correct in our breadth and market internals estimation, indices may pause and create a pennant that is often associated with period of a shallow consolidation before momentum reemerges to the upside. With a 'cup and handle' pattern, you have a gradual rounded bottom pattern, and that's a shift in trend bias. You lose sellers and gain buyers. Then, you have a secondary saucer-like pattern that develops above the bigger rounded pattern. A 'cup and handle' is a technical observation that is often associated with accumulation tendencies and usually results on the upside. I would say 'pole and pennant' is the one that I see a lot among U.S. stocks. Within Canada, we see a lot more rounded 'cup and handle' patterns. And a 'cup and handle' pattern is often seen within commodity indices or commodities, in general. So, both patterns suggest the S&P/TSX Composite Index and the S&P 500 will exhibit a pause in momentum, or consolidation period, after which they will resume their uptrends? Correct. And how long do you anticipate that pause or consolidation phase will last? The consolidation is shallow in amplitude. In other words, dips are shallow. And the phase of consolidation is not an elongated one. It lasts weeks to a month or two. So, we think by summer, as we go into July, we should be at higher levels for both the S&P 500 and the TSX Composite Index. So, the adage 'sell in May and go away', might instead be 'buy the dips in June and go away'? I genuinely think that's the case. I think 'sell in May and go away' is the wrong narrative. Market internals are very healthy. They have improved significantly. Breadth is in good shape. We see broader participation of many individual names in both the U.S. and Canada and momentum conditions are good. So, any pushback in the month of June should be a buying opportunity. In fact, since the secular bull market began in 2009, when May is a strong month, you typically see follow-through strength into July. So, June dips are buying opportunities. So, I have a constructive bias, even based on seasonal characteristics. Are you maintaining your single-digit positive return forecasts for this year for both the S&P/TSX Composite Index and the S&P 500 Index? As of May 30, the year-to-date price return is nearly 6 per cent for the TSX and less than 1 per cent for the S&P 500. I am. My base case is either very low double-digits returns for both indices or high single-digit returns. During year one of the U.S. presidential cycle, the S&P 500 has a median return of 8.1 per cent and a hit rate of 58 per cent. (A hit rate is a measure of frequency of observations.) For the S&P/TSX Composite Index, the median return is 9.6 per cent, the hit rate is about 65 per cent. So you do have slightly higher relative observations for the TSX Index, also noting that, at least by our measures, we should be able to see better propensity for TSX index to hold itself better relative to the S&P 500 in the second half of the year. The S&P/TSX Composite Index broke above 26,000 for the first time last month and the S&P 500 is nearing 6,000. I know you're anticipating a potential pause in June, a shallow consolidation for a brief period, but if an uptrend does resume in the summer months where could these indices rise to? Fresh discovery becomes difficult once we begin to make new highs. For the TSX Composite Index, I am measuring 27,100 to as high as 27,500. That would be my amplitude measured move. For the S&P 500, 6,475 to as high as 6,500. And over what time period? I would not be surprised if we resolved that in the next few months. In a report that you published last month, you noted an improvement in growth and momentum factors and a rotation away from value, low volatility and dividend yield factors. Given your outlook for the uptrend continuation for major North American indices, will growth and momentum stocks continue to be the leaders? I think that's the case. We still see that factor rotation favouring growth and momentum. Offence versus defence is certainly showing a better technical backdrop. I looked at four sectors and put them together on an equal-weight basis, and they were financials, consumer discretionary, industrials and technology, and divided them by utilities and staples. So, I put the offensive sectors in the numerator and defensive sectors in the denominator, and there is a technical chart that shows this ratio does have better upside potential, which favours strength in the numerator or weakness in the denominator. Was that analysis looking at sectors in the S&P/TSX Composite Index? That was for the TSX. For the U.S., we see the same thing. For the U.S., we found that defence is also resting. We're seeing utilities pausing and drifting, staples pausing and drifting, but against them we're seeing technology leading and sharply showing strength. We're seeing financials continuing to show better relative and absolute performance. We also see 'Magnificent Seven' stocks starting to show a very strong set of positive reversals, and that's a very big weighting in the S&P 500. When we spoke in January, you said, 'Bitcoin is a vehicle that is slowly becoming of asset allocation importance.' You added that given the strong run, the price of Bitcoin could dip to US$80,000 or lower, which would mark a good level to revisit the cryptocurrency. Your forecast was accurate. In April, Bitcoin fell below US$80,000 before surging to a record high in May. What is your current outlook for Bitcoin? I noticed in your matrix table that ProShares Bitcoin ETF (BITO-A) jumped in its rankings last month and entered the top 10. Like the markets where we see a pause and refresh, this should also be applied to Bitcoin and cryptos. We don't see Bitcoin falling below US$90,000 on a pullback. We think it would be a shallow correction. On the upside, we measured it to be closer to US$137,000 to as high as US$150,000 for Bitcoin so there's a lot of upside for Bitcoin, in our opinion. We're also seeing miners that are associated with cryptocurrency mining show better moving internals. Miners are showing positive reversals and better improving technical backdrops. Could you highlight a couple of them for our readers? In Canada, there's Galaxy Digital (GLXY-T), which recently had a sharp move and has now pulled back. I think this pullback can provide another opportunity given the pullback is on thinner volume and we're already seeing a 'golden cross' pattern within Galaxy Digital. There's one in the U.S. that everybody looks at called Strategy (MSTR-Q), formerly known as MicroStrategy. That's another good one that is showing better share price action. Both the 50-day and 200-day moving averages are marginally rising. This is a very constructive pattern for Strategy. Do you have technical targets for Galaxy and Strategy? For Galaxy, we are looking at revisiting the previous high. In other words, we should get back to a $35 handle and we should also be able to push through $35 on the upside. We measure that move to potentially be to $44, $45 levels. Strategy should be able to get back to north of US$460, US$480 from where it is. This is effectively a chart that is heavily tied to Bitcoin. Are there other thematic ETFs that are exhibiting major moves, either higher or lower, in your matrix? We still like silver and gold. We had a pause because of their seasonality. We saw a slower pace of advance in the miners, VanEck Gold Miners ETF (GDX-A), VanEck Junior Gold Miners (GDXJ-A) and Global X Silver Miners ETF (SIL-A). These ETFs are showing positive reversals. Seasonal strength for both silver and gold tends to become stronger as you go into the end of the summer. Here too, I estimate that dips will be able to provide a buying opportunity for anyone whose interested in this space. We like gold. We like silver. Silver has underperformed. I think that gives silver better potential buoyancy relative to gold. Last month, you added TD Bank to your top 10 best ideas basket and you had an initial price target of $94. The share price closed the month of May at $94.77. Your technical target was spot on. This month, you removed TD from your top 10 list and replaced it with Sun Life. However, I noticed in your technical scorecards that multiple bank stocks continue to rank well. We find some of the insurance names to be less overbought relative to banks. I am of the view that banks have already put out a great set of earnings and a lot of good news may already be discounted in the share price. So, I would not be surprised to see a period of consolidation or a pause among the banks and maybe a rotation in favour of lifecos. The recent technical breakout in Sun Life share price is still new from a time horizon perspective, with a momentum buy signal that was triggered only three weeks ago. It is reasonable to suggest that many alpha capture models are likely overweight Sun Life stock. It has a durable relative strength backdrop. It ranks well in our matrix process with a big increase in its delta - month over month rank. Fundamentally, our desk is also positive on SLF based on continued profit improvement in the U.S., earnings growth, growth in Asia and share buybacks. Earnings per share estimates are coming in above consensus and there could be further upside if our views are correct for the U.S. equity markets head higher into summer. And your technical target for Sun Life is? We are measuring $93.10 to as high as $95 for Sun Life on the upside. I noticed that half of the securities on your top 10 best ideas list are at or very close to all-time highs, those being Power Corp, Sun Life, EIC, MDA and NGEx Minerals. They're not looking overbought or overextended to you then? We do believe the stocks that make 52-week highs are likely to make new 52-week highs as time progresses just because momentum begets momentum. It's also a relative ranking for me. So, Power Corp. is a defensive name. I always have to be balanced in my view when we construct a basket of top 10 best ideas to make sure that I have a cushion in case there is a measure of defence that develops during the month. So, I think Power Corp. fits that call. Power has already broken out of its range, and pullbacks should be supported. MDA is poised to breakout, I'm measuring $34 to as high as $36. It has a flat top that has been in place for the past 12 months and has gone to this same reference point a few times, and I think if you knock on the same door often, it will open for you. Parkland is an interesting addition to your top 10 best ideas list as it has a potential near-term potential catalyst. They received a takeover offer, which shareholders will vote on later this month. I've had this name in our basket in the past and I think this is a name that has a backdrop of a shift in trend, i.e. a 'golden cross' condition, which is your 10-week moving average over the 40-week moving average. Also, there's been a lot of positive divergences throughout the past six months. By divergences, I mean momentum has been showing bottom building - that's positive divergence. The breakout above $37 for PKI established what's called a 'double bottom' technical pattern that should bring about a measured move north of $42. So, I'm thinking PKI below $40 is attractive. Earlier you remarked on the importance of having a very balanced portfolio. Given the need to have a diversified portfolio, is there a stock that would have appeared on your top 10 best ideas list but due to sector constraints you weren't able to include it? AGF (AGF-B-T) is a great name. It has a positive trend shift in our work. It has a reasonable yield and a good longer-term relative strength shift. AGF is a name that we like, but it's also a name that is not liquid enough. But nonetheless, I do know the sentiment for AGF is positive. Technical scores and quantitative factors for AGF are positive. It's a good name that continues to show a $14 handle as a measured move. It's not added because there are other more liquid names that stand above it. Looking at global investment opportunities, European ETFs continue to rank well. In your global regional ETF matrix, the top five ranked ETFs, starting with number one, are the Global X MSCI Greece ETF (GREK-A), followed by the iShares MSCI Italy ETF (EWI-A), the iShares MSCI Spain ETF (EWP-A), and then two German ETFs - the iShares MSCI Germany ETF (EWG-A) and Franklin FTSE Germany ETF (FLGR-A). Do technical indicators suggest that the strength in European markets will remain intact or do you think this rotation to growth and momentum factors may lift U.S. focused ETFs? We find a very deeply oversold condition that favours the S&P 500 from a mean reversion perspective over iShares MSCI ACWI ETF (ACWI-Q), the All Country World Index. So, we would not be surprised to see a pause or consolidation with some of these strong runners like Greece, Italy or Germany or other regions compared to S&P 500, which is not as overbought. I do admit that my ranking order is still keeping the S&P 500 on the lower side. The U.S. has come up in its ranking to number 51 out of 64 that we monitor, a 10-point delta relative to previous months. So, the U.S. has come up but it's still in the lower bucket of our ranking process. An interesting move I saw was move higher in the iShares MSCI Hong Kong ETF (EWH). It ranked number 36 in your regional ETF matrix on April 29, and the latest figure I saw was number 7. We like Hong Kong. We like Japan. iShares MSCI Hong Kong ETF (EWH) and iShares MSCI Japan ETF (EWJ) both exhibit a very good technical backdrop, they're not overbought by any measure, and I think that it's reasonable to make the case that if you want to diversify from the away from the U.S., having exposure to those parts of the world would not be a bad idea. Generally speaking, we like iShares MSCI EAFE ETF (EFA-A). We still think that the U.S. dollar is probably going to stay at best flat to lower, and that should be able to buoy a lot of those regions. But, I am very cognizant that if we're correct about our estimation about the 'pole and pennant' pattern that has been developing and the V-shaped recovery that is developing within the 'Magnificent Seven' and with some of the U.S. mega-cap stocks, I would not be surprised to see the S&P 500 perform relatively better in the weeks, months ahead compared to Europe or other regions. Anything else that you want to mention to readers? We're seeing good breadth expansion within the REIT space in Canada. So, InterRent REIT (IIP-UN-T) was acquired last month. We saw a big move in the broader REIT space in Canada and we're seeing a better follow-through in the likes of Killam Apartment REIT. So, we added KMP to our basket. Killam is currently trading at $19 and change, it has a very strong band of support at $18.50, and notable upside potential closer to $20.50. It also has a good yield, so I think Killam is a good name to have in our basket. But it's not just KMP, we see a broad improvement within the REIT space. Breadth in TSX REITs has notably improved with the members having broadly recovered above their medium and longer-term averages. Both BMO Equal Weight REITs Index ETF (ZRE-T) and iShares S&P/TSX Capped REIT Index ETF (XRE-T) are showing better durability in their momentum readings that should support the sector from a buy the dip perspective. This Q&A has been edited for brevity and clarity.
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
Energy and tech stocks help lift S&P/TSX composite, U.S. stocks also higher
TORONTO – Canada's main stock index was up in late-morning trading, helped by strength in energy and technology sectors, while U.S. stock markets also climbed higher. The S&P/TSX composite index was up 81.84 points at 26,424.13. In New York, the Dow Jones industrial average was up 353.70 points at 42,673.44. The S&P 500 index was up 53.32 points at 5,992.62, while the Nasdaq composite was up 198.88 points at 19,497.33. The Canadian dollar traded for 73.04 cents US compared with 73.21 cents US on Thursday. The July crude oil contract was up US$1.10 at US$64.47 per barrel and the July natural gas contract was up two cents US at US$3.70 per mmBTU. The August gold contract was down US$23.10 at US$3,352.00 an ounce and the July copper contract was down five cents US at US$4.88 a pound. Monday Mornings The latest local business news and a lookahead to the coming week. This report by The Canadian Press was first published June 6, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD
